NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Employees

1,453

Sector

Medical Equipment, Supplies & Distribution

Calendar

09:00pm - International Association for the Study of Lung Cancer World Conference

More about the company

Quotes

Date	Price	Change	Volume
24-09-09	16.57 $	-1.84%	386,292
24-09-06	16.88 $	-6.48%	1,193,828
24-09-05	18.05 $	+8.08%	1,877,129
24-09-04	16.70 $	-0.30%	1,570,193
24-09-03	16.75 $	-13.84%	3,047,602

Delayed Quote Nasdaq, September 06, 2024 at 04:00 pm EDT

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

16.88USD

Average target price

25.86USD

Spread / Average Target

+53.18%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 02:51:21 2024-09-09 pm EDT			5-day change	1st Jan Change
16.56 ^USD	-1.93%		-1.01%	+11.05%

Sep. 03	NovoCure CEO Asaf Danziger to Retire, CFO Ashley Cordova Named Successor	MT
Sep. 03	Novocure Announces CEO Changes, Effective January 1, 2025	CI

Capitalization	1.83B	P/E ratio 2024 *	-12.5x	P/E ratio 2025 *	-11.9x
Enterprise value	1.89B	EV / Sales 2024 *	3.26x	EV / Sales 2025 *	3.49x
Free-Float	90.78%	Yield 2024 *	-	Yield 2025 *	-

NovoCure CEO Asaf Danziger to Retire, CFO Ashley Cordova Named Successor	Sep. 03	MT
Novocure Announces CEO Changes, Effective January 1, 2025	Sep. 03	CI
Novocure Announces Management Changes	Sep. 03	CI
NovoCure Q2 Loss Narrows, Net Revenue Increases	Jul. 25	MT
Transcript : NovoCure Limited, Q2 2024 Earnings Call, Jul 25, 2024	Jul. 25
Earnings Flash (NVCR) NOVOCURE Posts Q2 Revenue $150.4M, vs. Street Est of $135.8M	Jul. 25	MT
Earnings Flash (NVCR) NOVOCURE Reports Q2 Loss $-0.31 Per Share, vs. Street Est of Loss $-0.40 Per Share	Jul. 25	MT
NovoCure Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	Jul. 25	CI
NovoCure Limited(NasdaqGS:NVCR) dropped from Russell Midcap Growth Index	Jun. 30	CI
NovoCure Limited(NasdaqGS:NVCR) dropped from Russell 1000 Index	Jun. 30	CI
NovoCure Limited(NasdaqGS:NVCR) added to Russell 2000 Index	Jun. 30	CI
NovoCure Limited(NasdaqGS:NVCR) added to Russell 2000 Growth Index	Jun. 30	CI
NovoCure Limited(NasdaqGS:NVCR) dropped from Russell Midcap Index	Jun. 30	CI

Wedbush Adjusts Price Target on NovoCure to $24 From $21, Maintains Neutral Rating	Jun. 04	MT
Piper Sandler Raises NovoCure's Price Target to $28 From $25, Maintains Overweight Rating	Apr. 10	MT
Wells Fargo Cuts Price Target on NovoCure to $42 From $49, Keeps Overweight Rating	Apr. 03	MT
Evercore ISI Adjusts Price Target on NovoCure to $15 From $14, Keeps In Line Rating	Feb. 23	MT
Wedbush Adjusts NovoCure Price Target to $21 From $23, Maintains Neutral Rating	23-10-26	MT

NovoCure Limited Stock

Equities

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Valuation: NovoCure Limited

Chart: NovoCure Limited

Latest news: NovoCure Limited

Last Transcript: NovoCure Limited

Analysts' recommendations: NovoCure Limited

Press Releases: NovoCure Limited

News in other languages: NovoCure Limited

Quotes and Performance

Course Extremes

Managers and Directors: NovoCure Limited

ETFs: NovoCure Limited

Medical Equipment

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly earnings, Rate of surprise

Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy	07:03am	BU
Novocure Announces Planned CEO Transition	Sep. 03	BU
Novocure to Participate in 2024 Wells Fargo Healthcare Conference	Aug. 28	BU
Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer	Aug. 14	BU
NovoCure: Q2 Earnings Snapshot	Jul. 25	AQ

TIGER-Studie berichtet über neue Überlebensergebnisse der TTFields-Therapie bei neu diagnostizierten Glioblastom-Patienten in Deutschland	May. 24
Klinische Phase-3-Studie METIS erreicht primären Endpunkt und zeigt eine statistisch signifikante Verlängerung der Zeit bis zur intrakraniellen Progression bei Patient:innen mit Hirnmetastasen von nicht-kleinzelligem Lungenkrebs	Mar. 28
L’essai clinique de phase 3 METIS a atteint son critère principal, démontrant un allongement statistiquement significatif du délai médian jusqu’à la progression intracrânienne chez les patients porteurs de métastases cérébrales consécutives...	Mar. 28
Aktien New York Schluss: Anleger greifen nach Rücksetzer wieder zu	Mar. 27
El ensayo clínico de fase 3 LUNAR demuestra un aumento estadísticamente significativo y clínicamente relevante de la supervivencia global en pacientes con cáncer de pulmón no microcítico metastásico tras terapias con platino	23-06-06

1 day	-6.48%
1 week	-13.17%
Current month	-13.17%
1 month	-12.49%
3 months	-21.49%
6 months	+2.06%
Current year	+13.06%

Director	Title	Age	Since
Asaf Danziger CEO	Chief Executive Officer	57	01-12-31
Ashley Cordova DFI	Director of Finance/CFO	45	14-05-31
Nicolas Leupin CTO	Chief Tech/Sci/R&D Officer	50	Jan. 03

Name	Weight	AuM	1st Jan change	Investor Rating
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD	0.81%	0 M€	0.00%	-
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD	0.71%	0 M€	0.00%	-
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY	0.19%	18 M€	+6.84%	-

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
NOVOCURE LIMITED	-6.48%	-13.17%	-15.73%	-87.59%	1.83B
SHOCKWAVE MEDICAL	-0.01%	+0.01%	+48.43%	+45.94%	12.57B
PENUMBRA, INC.	-0.15%	+0.70%	-30.46%	-25.08%	7.91B
MASIMO CORPORATION	-2.40%	-5.10%	+5.85%	-59.22%	5.96B
GETINGE AB	+0.62%	+3.58%	+16.08%	-40.47%	5.8B
ASAHI INTECC CO., LTD.	+0.71%	+5.61%	-8.01%	-17.43%	5.25B
APT MEDICAL INC.	+0.93%	+7.31%	+50.09%	+64.25%	5.06B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	-1.10%	-5.23%	-4.25%	-3.00%	4.43B
INARI MEDICAL, INC.	+9.21%	+5.30%	-30.96%	-44.31%	2.65B
SKAN GROUP AG	+0.51%	-2.22%	0.00%	+68.30%	2.11B
Average	+0.18%	-0.41%	+3.10%	-9.86%	5.36B
Weighted average by Cap.	+0.09%	+0.33%	+10.78%	-2.28%

Manager	Title	Age	Since
Asaf Danziger CEO	Chief Executive Officer	57	01-12-31
Bill Doyle CHM	Chairman	61	03-12-31
Kin Yip Leung BRD	Director/Board Member	63	11-08-04

	2024 *	2025 *
Net sales	580M	616M
Net income	-146M	-154M
Net Debt	65.66M	324M